Expert Review of Pharmacoeconomics and Outcomes Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China
CONCLUSIONS: Sin+Chemo is a cost-effective first-line treatment option for advanced HER2-negative GC/GEJC in China.CLINICAL TRIAL REGISTRATION: ORIENT-16, www.clinicaltrials.gov, identifier is NCT03745170.PMID:38594905 | DOI:10.1080/14737167.2024.2341859 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 10, 2024 Category: Health Management Authors: Wei Li Li Wan Source Type: research

Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023
Expert Rev Pharmacoecon Outcomes Res. 2024 Apr 9:1-3. doi: 10.1080/14737167.2024.2339945. Online ahead of print.NO ABSTRACTPMID:38591254 | DOI:10.1080/14737167.2024.2339945 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 9, 2024 Category: Health Management Authors: Micka ël Hiligsmann Mitchell P DeKoven Riddhi Doshi Carolyn Gotay Carlo Lazzaro Jayashri Sankaranarayanan Rayya Hajjar Source Type: research

Economic burden of type-2 diabetes in Peru: a cost-of-illness study valuing cost differences associated with the level of glycemic control
CONCLUSIONS: T2DM places a heavy burden on the Peruvian healthcare budget that will be even greater if poor glycemic control is maintained.PMID:38584495 | DOI:10.1080/14737167.2024.2333337 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 8, 2024 Category: Health Management Authors: Janice Seinfeld Alfredo Sobrevilla Mar ía Laura Rosales Mauricio Ib áñez Delia Ruiz Eduardo Penny Sergio Londo ño Source Type: research

The impact of bone turnover marker on medication adherence and the health economics-related consequences
Expert Rev Pharmacoecon Outcomes Res. 2024 Apr 3:1-4. doi: 10.1080/14737167.2024.2337718. Online ahead of print.NO ABSTRACTPMID:38568796 | DOI:10.1080/14737167.2024.2337718 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 3, 2024 Category: Health Management Authors: Nannan Li Niklas Rye J ørgensen Jean-Yves Reginster Micka ël Hiligsmann Source Type: research

Learnings from cross-border biosimilar pricing policies in Europe
Expert Rev Pharmacoecon Outcomes Res. 2024 Mar 26:1-4. doi: 10.1080/14737167.2024.2334343. Online ahead of print.NO ABSTRACTPMID:38530083 | DOI:10.1080/14737167.2024.2334343 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 26, 2024 Category: Health Management Authors: Steven Simoens Teresa Barcina Lacosta Andr ás Inotai Source Type: research